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Peripheral neuropathy has been associated with structural and functional changes of 
the amygdala, a key player in emotions. Here we study whether peripheral neuropathy 
influences pain regulation by the amygdala. For this purpose, we determined 
discharge rates of presumably pro- and antinociceptive pain-regulatory neurons in the 
rostral ventromedial medulla (RVM) following microinjection of various 
glutamatergic compounds into the central nucleus of the amygdala. RVM neurons 
were recorded in pentobarbitone-anesthetized rats with a peripheral nerve injury or 
sham-operation. In a separate behavioral experiment, we determined whether the 
influence of amygdaloid administration of a glutamatergic compound on affective 
pain-related behavior, as assessed by an aversive place-conditioning test, is changed 
by neuropathy. While glutamate or an NMDA receptor antagonist in the amygdala 
failed to induce marked changes in discharge rates of RVM cells, amygdaloid 
administration of DHPG, a group I metabotropic glutamate receptor (mGluR) agonist 
acting on mGluR1 and mGluR5, increased discharge rates of presumably 
pronociceptive RVM ON-cells in nerve-injured but not sham-operated animals. This 
pronociceptive effect of DHPG was reversed by MPEP (mGluR5 antagonist) and 
CPCCOEt (mGluR1 antagonist). CHPG, an mGluR5 agonist, failed to influence ON-
cell activity and DHPG failed to influence activity of presumably antinociceptive 
RVM OFF-cells.  Amygdaloid administration of DHPG increased and that of 
CPCCOEt decreased affective pain-related behavior in nerve-injured animals. The 
results suggest that following nerve injury, the amygdaloid group I mGluR, 
particularly subtype mGluR1, has an enhanced pronociceptive effect providing a 
potential mechanism for emotional enhancement of pain in peripheral neuropathy. 
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Introduction 
 
 The amygdala is a major player in emotions (Phelps and LeDoux, 2005). It 
also receives ascending nociceptive signals (Bernard et al., 1996) and it has efferent 
projections to structures that are involved in pain modulation (e.g., Rizvi et al., 1991; 
Van Bockstaele et al., 1996). These findings, together with chemical or electrical 
stimulation and lesion studies (see below), indicate that the amygdala has a role in 
pain modulation. Interestingly, the role is dual one varying from antinociception 
(Helmstetter and Bellgowan, 1993; Helmstetter et al., 1998; Manning and Meyer, 
1995; McGaraughty and Heinricher, 2002; Mena et al., 1995; Nandigama and 
Borszcz, 2003) to pronociception (Greenwood-Van Meerveld, 2001; Manning, 1998; 
Quin et al., 2003).  
 
 Sustained nociception produces synaptic plasticity in the amygdala. This has 
been shown in electrophysiological recordings performed in animals with 
inflammatory pain (Neugebauer et al., 2004; Neugebauer, 2006) and in control 
animals following tetanic stimulation of the parabrachial nucleus that relays 
nociceptive inputs to the amygdala (Lopez de Armentia and Sah, 2007).  Peripheral 
nerve injuries may cause chronic neuropathic pain that is associated with plastic 
changes in pain-mediating (Woolf and Salter, 2006) and -regulating (Almeida et al., 
2006; Pertovaara, 2000; Porreca et al., 2002) pathways. Recent studies indicate that 
peripheral nerve injury induces neural plasticity in the amygdala, as shown by 
increased postsynaptic currents evoked by ascending inputs (Ikeda et al., 2007) and  
generation of new amygdala neurons (Gonçalves et al., 2008). These findings still 
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leave open whether the pain regulatory role of the amygdala is changed by peripheral 
nerve injury.  
 
 In the present study we test a hypothesis that peripheral nerve injury 
influences pain regulation by the amygdala. Partial support for this hypothesis is 
provided by a recent finding showing that amygdaloid activation by glutamate 
suppressed presumably antinociceptive neurons in the noradrenergic locus coeruleus 
of nerve-injured animals (Viisanen and Pertovaara, 2007). To test further this 
hypothesis, we determined whether administration of glutamatergic compounds into 
the amygdala has a differential influence on discharge rates of putative pain-
regulatory neurons in the rostroventromedial medulla (RVM) of nerve-injured versus 
sham-operated animals.  For this purpose, we recorded discharge rates of presumably 
pronociceptive ON-cells and antinociceptive OFF-cells in the RVM (Fields et al., 
2006). Moreover, we assessed whether the effect by amygdaloid administration of a 
glutamatergic compound on affective pain-related behavior in an aversive place-
conditioning test is changed following peripheral nerve injury. 
 
  
Materials and methods 
 
 The experiments were performed in adult, male Hannover-Wistar rats 
weighing 180-190 g at the beginning of the experiment (Harlan, Horst, The 
Netherlands). The experimental protocol was accepted by the Institutional Ethics 
Committee and the experiments were performed according to the guidelines of 
European Communities Council Directive of 24 November 1986 (86/609/EEC). All 
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efforts were made to minimize animal suffering and to use only the number of 
animals necessary to produce reliable scientific data.  
 
Techniques for producing neuropathy 
 
 The unilateral axotomy and ligation of the tibial and common peroneal nerves 
was performed under pentobarbitone anesthesia (50 mg/kg i.p.) as described in detail 
earlier (Decosterd and Woolf, 2000; Gonçalves et al., 2007). Briefly, the skin of the 
lateral surface of the thigh was incised and a section made directly through the biceps 
femoris muscle exposing the sciatic nerve and its three terminal branches. Following 
ligation and removing 2-4 mm of the distal nerve stumps of the tibial and common 
peroneal nerves, muscle and skin were closed in two layers.  In sham-operated 
animals, the surgical procedure was identical, except that the tibial and common 
peroneal nerves were not ligated or sectioned. After the surgery, the animals were 
allowed to recover before the actual testing that was performed either one or eight 
weeks after the operation.           
 
Behavioral verification of neuropathy 
 
 Development of hypersensitivity was verified behaviorally in animals 
habituated to the experimental conditions 1-2 h daily for 2 to 3 days. For assessment 
of tactile allodynia, the hind limb withdrawal threshold was determined stimulating 
the sural nerve area in the hind paw of the operated limb with monofilaments. The 
calibrated series of monofilaments used in this study produced forces ranging from 
0.16 to 15 g (North Coast Medical, Inc. Morgan Hill, CA, USA. The monofilaments 
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were applied to the foot pad with increasing force until the rat withdrew its hind limb. 
The lowest force producing a withdrawal response was considered the threshold. The 
threshold for each hind paw of each rat was based on three separate measurements 
and the median of these values was considered to represent the threshold. Threshold 
values <1 g were considered to represent hypersensitivity. It should be noted that the 
currently used strain of rats delivered by Harlan (Horst, Netherlands) has an 
exceptionally low withdrawal threshold to monofilament stimulation in baseline 
(unoperated) condition: in ten unoperated control animals the lowest withdrawal 
threshold was only 4 g and therefore, the criterion for hypersensitivity was set to as 
low as <1 g in this study as we did earlier with the same strain of animals (Gonçalves 
et al., 2007).  
     
Electrophysiological recordings 
 
 For electrophysiological recordings the anesthesia was induced by 
pentobarbitone at a dose of 50 mg/kg i.p. and the animal was placed in a standard 
stereotaxic frame according to the atlas of Paxinos and Watson (1998). Anesthesia 
was maintained by infusing pentobarbitone (15-20 mg/kg/h). The level of anesthesia 
was frequently monitored by observing the size of the pupils and by assessing 
withdrawal responses to noxious stimulation. When necessary, the infusion rate of 
pentobarbitone was adjusted to keep the level of anesthesia steady. Although a change 
in the level of anesthesia may significantly influence neuronal responses, anesthesia is 
not likely to explain differences among different experimental groups and drug 
treatments in the present study. This, because anesthesia was induced and maintained 
in an identical manner in all experimental conditions. The rats were spontaneously 
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breathing. A warming blanket was used to maintain body temperature within 
physiological range. Peripheral perfusion was checked by evaluating the color of ears 
and extremities.  The skull was exposed and a hole drilled for placement of recording 
electrode in the RVM. The desired recording site in the RVM was 1.8-2.3 mm 
posterior from the ear bar, 0.4-0.9 mm lateral from the midline, and 8.9-10.7 mm 
ventral from the dura mater (Fig. 1).  
 Single neuron activity was recorded extracellularly with lacquer-coated 
tungsten electrodes (tip impedance 3-10 MΩ at 1 kHz) and then amplified and filtered 
using standard techniques. Data sampling was performed with a computer connected 
to a CED Micro 1401 interface and using Spike 2 software (Cambridge Electronic 
Design, Cambridge, U.K.).  
 Actual recordings did not start until the animal was under light anesthesia; i.e., 
the animals gave a brief withdrawal response to noxious pinch, but the pinch did not 
produce any longer lasting motor activity, nor did the animals have spontaneous limb 
movements. Neurons were classified based on their response to noxious pinch of the 
tail with a hemostatic clamp (Fig. 2). This stimulus was painful when applied to the 
finger of the experimenters. Neurons giving excitatory responses to pinch were 
considered ON-cells, those giving inhibitory responses were considered OFF-cells 
and neurons showing no or only a negligible (<10 %) change in their discharge rates 
as a response to pinch were considered NEUTRAL-cells. This classification scheme 
of medullary neurons was modified from that described by Fields and his co-workers 
(2006). A noteworthy difference is that we did not verify whether pinch-evoked 
responses of RVM neurons were associated with spinal reflex responses as in the 
original classification scheme (Fields et al., 2006). Therefore, the populations of ON- 
and OFF-cells in this study may not be identical with those in a study in which cells 
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are classified strictly according to the classification scheme of Fields and co-workers 
(2006). Our previous results suggest, however, that there is only little difference in the 
classification of RVM neurons whether or not spinal reflex responses are concurrently 
measured in lightly anesthetized animals (Pertovaara et al., 2001). 
 
Intracerebral drug injections 
 
 The animals had a guide cannula for drug administrations into the amygdala 
ipsilateral to the spared nerve injury or sham-operated limb (left side), except for one 
group that had the cannula contralateral to the nerve injury (right side), and a control 
group that had the cannula in the hippocampus. Additionally, a group of animals 
tested in behavioral experiments only had a bilateral guide cannula for drug injections 
into the central nucleus of the amygdala. For placement of the guide cannula (26 
gauge), the skull was exposed and a hole drilled for its placement. The desired 
injection site was in the central nucleus of the amygdala: 7.12 mm anterior from the 
ear bar, 3.40 mm lateral from the midline, and 8.00 mm ventral from the dura mater. 
A control injection site in a group of neuropathic animals was in the hippocampus, 
ipsilateral to nerve injury: 6.20 mm anterior from the ear bar, 1.00 mm lateral from 
the midline, and 3.20 mm ventral from the dura mater. The tip of the guide cannula 
was positioned 2 mm above the desired injection site. The cannula was fixed into the 
skull using a dental screw and dental cement. Drug administration to the brain and 
experimental protocols were performed one week after fixation of the guide cannula 
to the skull. When testing animals at the one-week postoperative time point, the guide 
cannula for amygdala injections was installed in the same operating session as sham 
or nerve surgery. When testing animals at the eight-week postoperative time point, the 
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guide cannula was installed in a separate session at least one week prior to 
electrophysiological recordings. 
  Drugs or saline control were microinjected into the amygdala through a 33-
gauge stainless steel injection cannula inserted through and protruding 2 mm beyond 
the tip of the guide cannula. The microinjection was made using a 10 µl Hamilton 
syringe that was connected to the injection cannula by a length of a polyethylene (PE-
10) tubing. The volume of injection was 0.5 µl. At this volume, the spread of the 
injected drugs within the brain was at least 1 mm (Myers, 1966). The efficacy of 
injection was monitored by watching the movement of a small air bubble through the 
tubing. The injection lasted 30 s and the injection cannula was left in place for an 
additional 30 s to minimize flow of the drug solution back up the injector track. At the 
completion of the experiment, the microinjection sites were histologically verified and 
plotted on a standardized section derived from the stereotaxic atlas of Paxinos and 
Watson (1998).  
 
Course of the electrophysiological study 
 
 There were four groups of animals that were included in the 
electrophysiological study and that had a guide cannula for amygdala injections 
ipsilateral to nerve injury or sham operation: i) sham group tested one week after 
operation, ii) sham group tested eight weeks after operation, iii) SNI group tested one 
week after operation, iv) SNI group tested eight weeks after operation. Additionally, 
there was a fifth group of SNI animals tested one week after operation that had the 
guide cannula for amygdala injections contralateral to nerve injury, and a sixth group 
of animals with neuropathy of one week duration that had the guide cannula for drug 
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injections into a control site in the hippocampus ipsilateral to nerve injury. In each of 
these groups, neuropathic hypersensitivity was verified with the monofilament test 
(see above) before the start of the electrophysiological experiment.    
 After induction of anesthesia, the microelectrode was lowered to the RVM. 
After finding a single cell, it was first classified based on its response to noxious tail 
pinch (see above) and then its spontaneous activity was recorded for two to three 
minutes. Next, one of the studied drugs or saline control was administered in a varied 
order to the amygdala and the spontaneous activity was recorded for up to 30 min 
(except with glutamate and MK-801 for six min). One to two drug conditions were 
tested in one cell, and one to four cells were tested in each animal. The minimum 
interval to the next drug testing condition was 30 min following saline or glutamate, 
while it was 60 min following other drugs, except for MK-801 that was always the 
last drug tested in each animal. When attempting to reverse the effect induced by the 
glutamatergic agonist DHPG, the antagonist was injected into the amygdala 
immediately (MPEP) or 15 min (CPCCOEt) before the agonist. In the data analysis, 
the discharge rate before injection was compared with the discharge rate determined 
after the injection. This was done by subtracting the mean post-injection discharge 
frequency during one min at various time points following microinjection from the 
mean discharge frequency before microinjection; i.e., a positive value represents 
increase of activity in the RVM by amygdala injection, and vice versa.    
 
Assessment of aversive avoidance behavior and its modulation by glutamatergic 
receptors of the amygdala   
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 Place avoidance test was performed, as described earlier (LaBuda and Fuchs, 
2000),  to obtain a measure of affective pain induced by mechanical stimulation of the 
neuropathic hind paw. Before testing, the animals were habituated to the test 
conditions by spending one to two hours daily for two days in the test box. In the 
actual testing, the rat was placed within a Plexiglas chamber (60 x 30 x 30 cm; one 
half of which was painted black on the external surface) placed upon an elevated 
metal grid. The rats were placed over the midline of the chamber and stimulation of 
the plantar surface of the hind paw initiated with a 60 g monofilament once every 15 s 
for 30 min. When residing within the dark side of the chamber the injured or sham-
operated hind paw was stimulated. Conversely, the non-operated hind paw was 
stimulated when residing within the light side of the chamber. Throughout the 30 min 
test period rats were allowed unrestricted movement throughout the chamber. The 
percent time spent in the light side of the chamber during the 30 min observation 
period was determined in each condition for each animal. It is assumed that the more 
aversive the mechanical stimulation of the hind paw, the more the animal spends time 
in the light side of the chamber; i.e., the place avoidance test is considered to assess 
affective-emotional pain behavior (LaBuda and Fuchs, 2000).  
 Three experimental groups of rats were tested in the place avoidance test: i) 
SNI animals with amygdaloid injections ipsilateral to the nerve injury ii) SNI animals 
with bilateral amygdaloid injections, iii) sham-operated animals with amygdaloid 
injections ipsilateral to the sham operation. In the bilateral treatment group, the drug 
conditions were saline, DHPG at the dose of 5 nmol or 10 nmol/amygdala (10 nmol or 
20 nmol/animal, respectively), and CPCCOEt at the dose of 20 nmol or 40 
nmol/amygdala (40 nmol or 80 nmol/animal/respectively). In the ipsilateral treatment 
groups, drug conditions were saline, 10 nmol of DHPG, or 40 nmol of CPCCOEt. In 
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all experimental conditions, drugs were administered into the amygdala immediately 
before the start of the place avoidance test. In each experimental group, each drug 
condition was assessed in a separate day, one to two weeks following nerve or sham 
injury. Each animal participated in three to four drug testing sessions, the interval in 
testing different drug conditions in one animal was at least two days. The order of 
testing different drug conditions was varied within the groups to avoid serial effects.   
 
Drugs 
 
 (S)-3,5-Dihydroxyphenylglycine (DHPG; an mGluR1 and mGluR5 agonist), 
(RS)-2-Chloro-5-hydroxy (CHPG; an mGluR5 agonist), 6-Methyl-2-
(phenylethynyl)pyridine (MPEP; an mGluR5 antagonist), (+)-MK-801 hydrogen 
maleate (MK-801; an NMDA-R antagonist) and glutamate were purchased from 
Sigma (St.Louis, MO) and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic 
acid ethyl ester (CPCCOEt; an mGluR1 antagonist) was purchased from Tocris 
(Bristol, U.K.). Physiological saline (OrionPharma, Espoo, Finland) was used for 
control injections. Drugs were dissolved in saline, except for CPCCOEt that was 
dissolved in DMSO. 
 Previous studies indicate that DHPG and CPCCOEt at the currently used dose 
of 10 nmol have proved effective in activating group I mGluRs within the currently 
used observation period of 30 min following intracerebral administration in the rat 
(e.g., Kim et al., 2007; Renoldi et al., 2007). Previous studies indicate that the 
currently used doses of glutamate (50 nmol) and MK-801 (3 nmol) induce a 
significant antinociception (Zhuo and Gebhart, 1997) or antiallodynia (Pertovaara and 
Wei, 2003), respectively, following supraspinal microinjection. The maximum 
 13
antinociceptive effect induced by central injection of glutamate has been obtained 
within two min (Zhuo and Gebhart, 1997), whereas the maximum antiallodynic effect 
induced by central injection of MK-801 was reached within 15 min (Pertovaara and 
Wei, 2003). Thus, the currently used observation period of 6 min following the 
injection of glutamate in the amygdala was appropriate for detecting the maximum 
effect induced by glutamate but only a submaximal effect induced by MK-801.  
 At the completion of the study, an electrolytic lesion was made in the 
recording site, the animals were given a lethal dose of pentobarbitone and the brains 
removed for verification of recording and microinjection sites. 
.  
Statistics 
 
 Data are presented as mean + S.E.M. One- or two-way ANOVA followed by 
Student-Newman-Keuls test or t-test (differences between two groups) were used for 
assessing differences between the experimental conditions. Grubb's test was used to 
exclude potential outliers (www.graphpad.com/quickcalcs/). P<0.05 was considered 
to represent a significant difference. 
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Results 
 
Response characteristics of RVM neurons 
 
 Spontaneous activity of RVM ON-cells was significantly influenced by SNI 
(F1,131=4.79, P=0.030; 2-w-ANOVA) and postoperative time point of testing 
(F1,131=4.19, P=0.043; 2-w-ANOVA). Post hoc tests indicated that the spontaneous 
discharge rate of ON-cells was increased in the SNI group one week after nerve 
injury, while eight weeks following injury it was reduced to the same level as in sham 
controls (Fig. 3 a). Spontaneous activity of RVM OFF-cells was influenced by 
postoperative time point of testing (F1,100=8.0, P=0.0057; 2-w-ANOVA), and this 
time-dependent effect varied with the experimental group (SNI versus sham; 
F1,100=4.50, P=0.036; 2-w-ANOVA). Post hoc tests indicated that the discharge rate of 
OFF-cells was significantly decreased one week following nerve injury, while eight 
weeks following injury it was at the same level as in sham controls (Fig. 3 b). In the 
present sample of neurons, postoperative time point of testing (one versus eight 
weeks) had no significant influence on spontaneous discharge rates of ON- or OFF-
cells in the sham control group (Fig. 3). 
 
Discharge rates of RVM cells following amygdaloid administration of glutamatergic 
compounds  
 
 When studying influence of glutamatergic compounds on discharge rates of 
RVM cells, the studied compounds were microinjected at a volume of 0.5 μl into the 
amygdala ipsilateral to nerve injury or sham operation, except for one group in which 
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it was injected into the amygdala contralateral to nerve injury. Microinjection of 
DHPG, an agonist of group I metabotropic glutamate receptor (mGluR) subtypes 
mGluR1 and mGluR5, at a dose of 10 nmol produced a significant increase in the 
discharge rate of RVM ON-cells in the SNI group (Fig. 4). DHPG induced the 
maximum increase in the discharge rate of ON-cells within five min, and the increase 
was of equal magnitude one and eight weeks following nerve injury (Fig. 5 a,b). The 
increase in the discharge rate of RVM ON-cells by 10 nmol of DHPG was of equal 
magnitude following its microinjection into the amygdala ipsi- (n=4) as contralateral 
(n=14) to the nerve injury in animals that were operated eight weeks before time point 
of testing (F=0.05; 2-w-ANOVA; not shown). CHPG, an mGluR5 agonist (10 nmol), 
failed to influence the discharge rate of RVM ON-cells in nerve-injured animals (Fig. 
5 b). The DHPG-induced increase of ON-cell activity in nerve-injured animals was 
completely reversed by pretreatment of the amygdala with MPEP, an mGluR5 
antagonist, at a dose of 50 nmol that produced no significant effect when administered 
alone (Fig. 5 c). The DHPG-induced increase of ON-cell activity in nerve-injured 
animals was also completely reversed by pretreatment of the amygdala with 
CPCCOEt, an mGluR1 antagonist, at a dose (40 nmol) that failed to produce a change 
in ON-cell discharge rate when administered alone (Fig. 5 d). Administration of 
DHPG at the dose of 10 nmol into a control site, the hippocampus, failed to produce 
any significant change on the discharge rate of five ON-cells (not shown) in 
neuropathic animals, while in one ON-cell DHPG administration into the 
hippocampus was followed at a 15 min post-injection time point by a sudden increase 
of the discharge rate from the pre-injection baseline rate by 384 % (not shown). 
According to Grubb's test, the RVM ON-cell with a sudden increase in the discharge 
rate 15 min following hippocampal injection of DHPG was a significant outlier 
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(P<0.05) and therefore, it was not included in the statistical assessment of the over-all 
effect.  
 DHPG (10 nmol) in the amygdala failed to influence OFF-cell activity in the 
SNI group, independent of postoperative time point (Fig. 6 a). Moreover, DHPG (10 
nmol) in the amygdala had no significant effect on discharge rates of ON- or OFF-
cells in the sham group (Fig. 6 b).  
 Microinjections of glutamate at a dose of 50 nmol or MK-801, an NMDA 
receptor (NMDA-R) antagonist, at a dose of 3 nmol failed to produce significant 
changes in the discharge rates of ON- or OFF-cells in the SNI or sham group (Fig. 7).  
 
Affective pain-related behavior following amygdaloid administration of DHPG or 
CPCCOEt 
 
 A behavioral place avoidance paradigm was used to assess whether 
amygdaloid administration of DHPG or CPCCOEt influences aversive quality of 
mechanical stimulation of the neuropathic hind paw. In sham-operated animals, 
mechanical stimulation of the operated hind paw induced no or negligible avoidance 
behavior, independent whether saline or DHPG (10 nmol) was injected into the 
ipsilateral amygdala (Fig. 8). In nerve-injured animals, mechanical stimulation of the 
neuropathic hind paw induced a marked avoidance behavior (as revealed by increased 
time spent in light) that was increased by administration of DHPG into the amygdala: 
while the increase of avoidance behavior induced by ipsilateral injection of 10 nmol 
of DHPG was short of significance, bilateral administration of DHPG produced a 
dose-related increase in place avoidance (F2,14=8.7, P<0.01; 1-w-ANOVA) that was 
significant at a dose of 10 nmol of DHPG/amygdala, corresponding to 20 nmol of 
 17
DHPG/animal (Fig. 8 a). In contrast, avoidance behavior was reduced by 
administration of CPCCOEt in the amygdala: while the decrease of avoidance 
behavior was short of significance following ipsilateral administration of 40 nmol of 
CPCCOEt, bilateral administration of CPCCOEt produced a dose-related decrease in 
place avoidance (F2,10=4.86, P<0.04; 1-w-ANOVA) that was significant at a dose of 
40 nmol of CPCCOEt/amygdala (Fig. 8 b). 
 
 
 
Discussion 
 
 In the present study, amygdaloid administration of DHPG, an mGluR1/5 
agonist, increased the discharge rate of presumably pronociceptive ON-cells in the 
RVM of nerve-injured but not sham-operated animals. This enhanced pronociceptive 
effect by was at least due to action on the amygdaloid mGluR1, since DHPG, an 
agonist of the mGluR1 and mGluR5, but not CHPG, an mGluR5 agonist, increased 
discharge rates of RVM ON-cells and this DHPG-induced effect was reversed by 
CPCCOEt, an mGluR1 antagonist. However, since MPEP, an mGluR5 antagonist, 
applied at a high dose also reversed the DHPG-induced increase of the ON-cell 
discharge rate, we cannot exclude contribution of the mGluR5 to the DHPG-induced 
pronociception. Administration of DHPG into a control site, the hippocampus, failed 
to produce a change in the discharge rate of RVM ON-cells in neuropathic animals. 
Amygdaloid administration of DHPG also failed to influence discharge rates of 
presumably antinociceptive OFF-cells of the RVM indicating that the nerve injury-
induced change was selective for the pronociceptive cell type. Since amygdaloid 
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administration of NMDA-R or group I mGluR antagonists alone failed to influence 
discharge rates of pro- or antinociceptive RVM cells, the amygdaloid NMDA-R or 
group I mGluRs may not contribute to tonic maintenance of neuropathic pain and 
hypersensitivity.  
In behavioral experiments of the present study, affective pain of nerve-injured 
animals was increased by amygdaloid administration of DHPG and decreased by 
CPCCOEt. Since the aversive place-conditioning test used in assessing affective pain-
related behavior (LaBuda and Fuchs, 2000) provides an emotional challenge 
putatively activating the amygdala, the decrease of affective pain by amygdaloid 
administration of an mGluR1 antagonist is in line with the hypothesis that emotions 
processed by the amygdala may enhance pain in nerve-injured animals, due to action 
on the amygdaloid mGluR1.    
 
Interaction between the amygdala and pain 
 
 Psychophysical studies suggest that emotions presumably processed by the 
amygdala produce significant changes in human pain reactivity (Craig, 2006). The 
direction of the change has varied from pain facilitation in anxious subjects to 
suppression of pain sensitivity in subjects with intense fear (Rhudy and Meagher, 
2000).  In line with this, previous studies in non-neuropathic animals have shown that 
the amygdala has a dual role in regulation of nociception varying from pronociception 
to antinociception (see the Introduction). There is accumulating  evidence indicating 
that sustained pain induces plastic changes in the amygdala (Neugebauer, 2006). Pain-
induced neural plasticity of the amygdala may influence its pain regulatory action as 
indicated by a recent study showing that activation of the extracellular signal-
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regulated kinase in the amygdala contributes to inflammatory hypersensitivity 
(Carrasquillo and Gereau, 2007). In addition to inflammation, peripheral neuropathy 
induces neural plasticity in the amygdala as shown by the findings that postsynaptic 
currents evoked by ascending inputs in the central amygdala were enhanced (Ikeda et 
al., 2007) and new amygdala neurons were generated (Gonçalves et al., 2008) 
following peripheral nerve injury. While the enhanced synaptic responses to 
ascending signals indicate that the relay of pain-related signals to the amygdala is 
facilitated in neuropathy (Ikeda et al., 2007), these previous results still left open 
whether the amygdala-induced pain regulation is changed by peripheral nerve injury. 
  
 In neuropathic animals, not only pain processing within the amygdala (Ikeda 
et al., 2007) but also pain regulatory influence of the amygdala may be changed as 
suggested by the following findings. Amygdaloid administration of a GABAA 
receptor agonist suppressed aversive pain-related behavior and hypersensitive spinal 
reflex responses in nerve-injured animals (Pedersen et al., 2007). This behavioral 
finding suggests that the amygdala may contribute to regulation of neuropathic 
hypersensitivity, possibly through action on descending pathways relaying in the 
RVM. Also, amygdaloid administration of glutamate suppressed presumably 
antinociceptive neurons in the noradrenergic locus coeruleus of nerve-injured but not 
sham-operated animals suggesting that activation of the amygdala may have a 
pronociceptive effect in peripheral neuropathy (Viisanen and Pertovaara, 2007). In 
line with this, the present results suggest that activation of the group I mGluR in the 
amygdala of nerve-injured animals promotes activity of presumably pronociceptive 
neurons in the RVM. Together these results suggest that the amygdala-induced pain 
modulation is changed in neuropathy. In neuropathic animals, activation of the 
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amygdala may promote hypersensitivity by, at least, two different types of actions on 
brain regulatory nuclei of the brainstem: by facilitating pronociceptive neurons in the 
RVM and by inhibiting antinociceptive neurons in the locus coeruleus. While the 
pronociceptive influence by the amygdala may be partly tonic in peripheral 
neuropathy (Pedersen et al., 2007), the present results with amygdaloid 
administrations of specific receptor antagonists alone suggest that the amygdaloid 
NMDA-R or group I mGluR do not explain the tonic pronociceptive action of the 
amygdala.   
 
Interestingly, while the enhancement of synaptic currents evoked by afferent 
inputs to the amygdala occurred predominantly in the central nucleus of the amygdala 
contralateral to peripheral nerve injury (Ikeda et al., 2007), the pronociceptive action 
of DHPG on the RVM was obtained following its amygdaloid administration ipsi- as 
well as contralateral to peripheral nerve injury. This result is in line with the earlier 
finding that activation of the amygdala ipsilateral to nerve injury attenuated 
presumably antinociceptive locus coeruleus neurons (Viisanen and Pertovaara, 2007) 
and it also fits the finding that the amygdala receives ascending nociceptive inputs 
from the ipsi- as well as contralateral body half (Bernard et al., 1996). It may be 
proposed that the enhancement of contralateral afferent inputs in the amygdala (Ikeda 
et al., 2007) and the pronociceptive change in the amygdala-induced pain regulatory 
effect that was observed also ipsilateral to nerve injury (Viisanen and Pertovaara, 
2007; the present results) have, at least partly, different underlying mechanisms.       
 
Glutamatergic receptor types sensitized in the amygdala  
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 Earlier results indicate that in arthritis, the responses of multireceptive neurons 
in the central nucleus of the amygdala are sensitized to administration of DHPG, an 
mGluR1 and mGluR5 agonist but not to CHPG, an mGluR5 agonist (Li and 
Neugebauer, 2004b; Neugebauer et al., 2003). This finding suggests that the 
amygdaloid mGluR1 plays a role in arthritic pain-related sensitization (Li and 
Neugebauer, 2004b; Neugebauer et al., 2003). The present results on the amygdaloid 
influence on the RVM and affective pain-related behavior extend this earlier finding 
by showing that a change in the function of the amygdaloid group I mGluR, and 
particularly the subtype mGluR1, may contribute to pain-related sensitization in 
peripheral neuropathy as well as in arthritis. In contrast, while the NMDA-R 
contributes to pain-related sensitization of amygdala neurons in arthritis (Li and 
Neugebauer, 2004a), a recent study indicated that sensitization of amygdala neurons 
in peripheral neuropathy is not dependent on the NMDA-R (Ikeda et al., 2007). In line 
with this, amygdaloid administration of an NMDA-R antagonist failed to induce a 
change in the discharge rate of RVM neurons in nerve-injured animals of the present 
study. While studies performed in non-neuropathic animals have provided evidence 
suggesting that the central nucleus of the amygdala plays a significant role in 
promoting affective pain behavior induced by noxious visceral stimulation, its lesion 
has attenuated place aversion induced by noxious cutaneous stimulation, too 
(Tanimoto et al., 2003), which finding is in line with the present results. It should be 
noted, however, that the currently administered injection volume of 0.5 μl into the 
central nucleus of the amygdala is likely to spread also to immediately adjacent areas 
(Myers, 1966), particularly other amygdaloid subnuclei. Therefore, we cannot exclude 
the possibility that the group I mGluRs e.g. in the basolateral nucleus of the amygdala 
contribute to the DHPG-induced pronociceptive effect in the present study. In a 
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distant control site, the hippocampus, DHPG, however, had no pronociceptive effect 
indicating that the pronociceptive effect was region-specific.  
 
Influence of the amygdala on discharge rates of RVM cells 
 
 An earlier study showed that microinjection of morphine into the basolateral 
nucleus of the amygdala produced antinociception that was accompanied by a 
decrease in the discharge rate of RVM ON-cells and an increase in the discharge rate 
of RVM OFF-cells, while morphine in the central or lateral nuclei of the amygdala 
failed to influence pain-related behavior or discharge rates of RVM ON- or OFF-cells 
(McGaraughty and Heinricher, 2002). Since the main amygdaloid output nucleus is 
the central nucleus receiving convergent information from various amygdaloid nuclei 
(Pitkänen et al., 1997), the antinociceptive effect by morphine in the basolateral 
nucleus was likely to be relayed to the RVM via the amygdaloid central nucleus. In 
the present study, DHPG was microinjected into the central nucleus of the amygdala, 
although the results do not allow excluding that group I mGluRs in adjacent 
amygdaloid subnuclei contributed to its pronociceptive effect. Together, earlier 
(McGaraughty and Heinricher, 2002) and the present results indicate that the 
amygdala has an influence on neuronal discharge rates in the RVM, a major pain 
regulatory region (Gebhart, 2004). The pain-regulatory effect originating in or 
relaying through the amygdala may have been mediated to the RVM directly 
(Hermann et al., 1997) or indirectly through the periaqueductal gray (Rizzi et al., 
1991). Moreover, efferent pathways other than those projecting directly or indirectly 
to the RVM may contribute to pain regulation by the amygdala. It should also be 
noted that the increased affective pain response to mechanical stimulation of the 
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neuropathic limb in the aversive place-conditioning task by the amygdaloid mGluR1 
may reflect increased afferent barrage evoked by the mechanical test stimulus due to 
increased RVM ON-cell activity, a distinct mechanism facilitating affective pain, or 
both.    
 
Spontaneous discharge rate of RVM cells following nerve injury 
 
 Increase in the ongoing discharge rate of RVM ON-cells and a decrease in the 
ongoing discharge rate of RVM OFF-cells have been associated with sustained 
hyperalgesia induced by inflammation (Kincaid et al., 2006). The cumulative results 
of the present and our preceding study (Gonçalves et al., 2007) support the hypothesis 
that an increased spontaneous discharge rate of RVM ON-cells and a decreased 
discharge rate of RVM OFF-cells contribute to maintenance of hypersensitivity also 
during the early phase (first week) of peripheral neuropathy in animals with SNI. 
During the late phase (eighth week) of neuropathy, the discharge rates of RVM ON- 
and OFF-cells were returned to control levels indicating that an abnormality in the 
ongoing discharge rate of RVM ON- or OFF-cells may not explain hypersensitivity 
induced by SNI. The return of the ongoing discharge rate to control levels during the 
late phase of SNI-induced neuropathy, however, does not exclude the possibility that 
the RVM ON- or OFF-cells contributed to maintenance of hypersensitivity through a 
change in the synaptic efficacy of their efferent connections. A change in the ongoing 
discharge rates of RVM ON- and OFF-cells is not pathognomic for the early phase of 
peripheral neuropathy in all experimental models as indicated by observations made 
in animals with ligation of the spinal nerves (Carlson et al., 2007; Pertovaara et al., 
2001) or chronic constriction of the sciatic nerve (Luukko and Pertovaara, 1993). 
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Additionally, peripheral nerve injury may induce enhanced responses of RVM cells to 
peripheral stimulation that potentially contributes to abnormal feedback regulation of 
ascending nociceptive signals (Carlson et al., 2007; Golçalves et al., 2007).    
 
Conclusions 
 
 Present results indicate that group I mGluRs in the amygdala may promote 
nociception in nerve-injured animals. This was shown by increased excitation of 
pronociceptive RVM ON-cells following amygdaloid administration of a group I 
mGluR agonist in neuropathic animals. Since the amygdala has a key role in 
processing emotions and since the administration of glutamatergic compounds into 
the amygdala potentially mimicks emotional activation of the amygdala, it may be 
proposed that activation of the amygdaloid group I mGluR, provides a possible 
mechanism for emotional enhancement of nerve injury-related hypersensitivity and 
pain. This proposal is supported by the behavioral finding indicating that amygdaloid 
administration of an mGluR1/5 agonist increased and that of an mGluR1 antagonist 
decreased affective pain-related behavior when the animal was exposed to an 
emotional challenge provided by the aversive place-conditioning test.   
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Legends for Figures 
 
 
Figure 1. Microelectrode recording sites in the RVM (left column) and microinjection 
sites in the amygdala (right column). The upper row shows an example of an 
electrolytic lesion made by the recording electrode in the RVM (left) and the track of 
the injection cannula in the amygdala (right). The rectangle and the circle in the 
schematic graphs of the lower row indicate the dorsolateral extent of areas, across 
several anteroposterior sections, in which the tips of medullary recording electrodes 
and amygdaloid microinjection cannulae were located, respectively. 
RVM=rostroventromedial medulla, CeA=central nucleus of the amygdala, 
Rmg=raphe magnus 
 
 
Figure 2. Examples of an RVM ON-cell (upper graph) and OFF-cell (lower graph) 
response to noxious pinch of the tail in a neuropathic animal. P_P indicates the 
duration of noxious tail pinch. The horizontal bars indicating tail pinch represent 5 s 
and the vertical calibration bars for the peristimulus time histograms represent 50 
imp/s. The insets show the shapes of the action potential. 
  
 
Figure 3. Spontaneous discharge rates of RVM ON-cells (a) and OFF-cells (b) in 
nerve-injured (SNI) and sham-operated animals. 1 and 8 wk (weeks) refer to the 
postoperative time point of testing. *P<0.05 (reference: the corresponding value in the 
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sham-operated group at the same postoperative time point). +P<0.05, +++P<0.005 
(Student-Newman-Keuls test; reference: the corresponding value at an earlier 
postoperative time point).  Error bars represent S.E.M. (n=19-29) 
 
 
Figure 4. Influence of DHPG (10 nmol; left column) or saline (right column) injection 
into the amygdala on the discharge rate of an RVM ON-cell in a neuropathic animal 
one week following the nerve injury. Time point of testing before and after the 
injection is shown above each row. The horizontal calibration bar represents 10 s and 
the vertical one 50 impulses/s. 
 
 
Figure 5. Discharge rates of RVM ON-cells in nerve-injured (SNI) animals following 
administration of group I metabotropic glutamatergic compounds into the amygdala 
ipsilateral to the nerve injury. (a) Time course of the effect by DHPG (10 nmol), an 
mGluR1 and mGluR5 agonist. (b) The effect by DHPG versus CHPG (10 nmol), an 
mGluR5 agonist. (c) Reversal of the DHPG-induced increase in the discharge rate by 
MPEP (50 nmol), an mGluR5 antagonist.   (d) Reversal of the DHPG-induced increase 
in the discharge rate by CPCCOEt (40 nmol), an mGluR1 antagonist. 
 1 and 8 wk (weeks) refer to the postoperative time point of testing. Sal=saline. 
MPEP=MPEP alone, CPCCO=CPCCOEt alone, +MPEP or +CPCCO=MPEP or 
CPCCOEt co-administered with DHPG. *P<0.05,**P<0.01, ***P<0.005 (Student-
Newman-Keuls test; In a, reference is the corresponding pre-injection value. In b, 
reference is the saline group. In c and d, reference is the DHPG group).  Error bars 
represent S.E.M. (nsal=16, nDHPG_1wk=8, nDHPG_8wk=14, nCHPG=4, nMPEP=5, n+MPEP=6, 
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nCPCCO=10, n+CPCCO=8). 100% (dotted horizontal line) represents the pre-injection 
discharge rate. 
 
Figure 6. (a) Discharge rates of RVM OFF-cells in nerve-injured (SNI) animals 
following administration of saline (Sal) or DHPG (10 nmol), an mGluR1 and mGluR5 
agonist, into the amygdala. (b) Discharge rates of RVM ON- and OFF-cells in sham-
operated animals following amygdaloid administration of saline or DHPG. 
 1 and 8 wk (weeks) refer to the postoperative time point of testing. Error bars 
represent S.E.M. (In a, nSal=6, nDHPG_1wk=9, nDHPG_8wk=6. In b, nSal=8, nDHPG_ON-cell=8, 
nDHPG_OFF-cell=5). 100% represents the pre-injection discharge rate. 
 
 
Figure 7.  Discharge rates of RVM cells following administration of glutamate 
(50 nmol) or MK-801 (3 nmol), an NMDA-R antagonist, into the amygdala.  (a) ON-
cells in nerve-injured (SNI) animals. (b) OFF-cells in nerve-injured animals. (c) ON- 
and OFF-cells in sham-operated animals.  
 1 and 8 wk (weeks) refer to the postoperative time point of testing. Sal=saline 
Error bars represent S.E.M. (n=6-10). 100% represents the pre-injection discharge 
rate. 
 
Figure 8. Behavior in aversive place-conditioning test following administration 
DHPG, an mGluR1 and mGluR5 agonist (a), or CPCCOEt, an mGluR1 antagonist (b), 
into the amygdala in nerve-injured (SNI) or sham-operated animals.  
 An increase in time spent in light is considered to reflect an increase in 
affective pain induced by monofilament stimulation of the hind paw. ipsi= 
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amygdaloid injection was performed only ipsilateral to the nerve injury/sham 
operation, bilat= amygdaloid injection was performed bilaterally. In the Y-axis, doses 
represent the dose/side; e.g., the dose 10 nmol represents 10 nmol/animal with 
ipsilateral injections and 20 nmol/animal with bilateral injections.  *p<0.05 (Student-
Newman-Keuls test; reference: the corresponding saline condition). Error bars 
represent S.E.M. (In a, nSNI-ipsi=9, nSNI-bilat=5, nSham-ipsi=5. In b, nSNI-ipsi=4, nSNI-bilat=4, 
nSham-ipsi=5).  
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